Kolexia
Lam You-Heng Gastro-entérologie
Lam You-Heng
Gastro-entérologie
Centre Hospitalier de Cholet
Cholet, France
51 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Adénocarcinome Tumeurs du côlon Tumeurs colorectales Tumeurs de l'oesophage Hémorragie Métastase tumorale Tumeurs du pancréas Tumeurs gastro-intestinales Instabilité des microsatellites

Collaborateurs

Voir plus
Capitain Olivier
Capitain Olivier
Ico - Site Paul Papin, Angers, France
Baudon Julien
Baudon Julien
Centre Hospitalier de Cholet, Cholet, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Touchefeu Yann
Touchefeu Yann
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Servier
22 collaboration(s)
Dernière en 2023
Sanofi
8 collaboration(s)
Dernière en 2022
Olympus
4 collaboration(s)
Dernière en 2023
Abbvie
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
LOGICAN: Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet Chemotherapy
Essai Clinique (Servier)   12 octobre 2023
629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
IROCAS: A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting
Essai Clinique (Unicancer)   30 août 2023
POCHI: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Re-visiting the Pronopall score ten years later: A multicenter retrospective study.
Bulletin du cancer   31 janvier 2022
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab: Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
Essai Clinique (Unicancer)   07 janvier 2022
Prognostic factors associated with upper gastrointestinal bleeding based on the French multicenter SANGHRIA trial.
Endoscopy international open   16 septembre 2021
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized Phase II Trial
Essai Clinique (Unicancer)   13 novembre 2020
Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.
Clinical colorectal cancer   19 octobre 2018
PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).
2018 ASCO Annual Meeting I   01 juin 2018